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and middle-income countries who test tuberculin
skin test positive using either a 5 mm or a 10 mm
cut-off: a systematic review
Andrew D Kerkhoff1,2*, Ankur Gupta3, Taraz Samandari4 and Stephen D Lawn2,3

Abstract
Background: A positive tuberculin skin test (TST) is often defined by skin induration of ≥10 mm in people who are
HIV-seronegative. However, to increase sensitivity for detection of Mycobacterium tuberculosis infection in the
context of impaired immune function, a revised cut-off of ≥5 mm is used for people living with HIV infection. The
incremental proportion of patients who are included by this revised definition and the association between this
proportion and CD4+ cell count are unknown.
Methods: The literature was systematically reviewed to determine the proportion of people living with HIV
(PLWH) without evidence of active tuberculosis in low and middle-income countries who tested TST-positive
using cut-offs of ≥5 mm and ≥10 mm of induration. The difference in the proportion testing TST-positive
using the two cut-off sizes was calculated for all eligible studies and was stratified by geographical region
and CD4+ cell count.
Results: A total of 32 studies identified meeting criteria were identified, providing data on 10,971 PLWH from
sub-Saharan Africa, Asia and the Americas. The median proportion of PLWH testing TST-positive using a
cut-off of ≥5 mm was 26.8% (IQR, 19.8-46.1%; range, 2.5-81.0%). Using a cut-off of ≥10 mm, the median
proportion of PLWH testing TST-positive was 19.6% (IQR, 13.7-36.8%; range 0–52.1%). The median difference in
the proportion of PLWH testing TST-positive using the two cut-offs was 6.0% (IQR, 3.4-10.1%; range, 0–37.6%).
Among those with CD4+ cell counts of <200, 200–499 and ≥500 cells/μL, the proportion of positive tests
defined by the ≥5 mm cut-off that were between 5.0 and 9.9 mm in diameter was similar (12.5%, 12.9% and
10.5%, respectively).
Conclusions: There is a small incremental yield in the proportion of PLWH who test TST-positive when using
an induration cut-off size of ≥5 mm compared to ≥10 mm. This proportion was similar across the range of
CD4+ cell strata, supporting the current standardization of this cut-off at all levels of immunodeficiency.
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Background
Tuberculin skin tests (TSTs) have for a long time been
used to define likely Mycobacterium tuberculosis (MTB)
infection, identify those who may benefit from isoniazid
preventive therapy and aid diagnosis of tuberculosis
(TB) disease, especially in children. While interferon
gamma release assays (IGRAs) were developed to improve the diagnostic accuracy for MTB infection, the
World Health Organization (WHO) does not recommend routine use of IGRAs in resource limited settings
due to cost, technical complexity and limited utility [1].
The sensitivity of TSTs for detecting MTB infection is
impaired among people living with HIV (PLWH) due to
an attenuation of cell-mediated responses, including a
reduction in memory CD4+ T cells at the TST site [2].
While a cut-off of ≥10 mm of induration is often used to
define a positive TST among those who are HIV seronegative, a cut-off of ≥5 mm is instead recommended by
the US Centers for Disease Control and Prevention
among PLWH to increase the sensitivity [3]. This revised
cut-off is based on unpublished data from New York
City in the 1980’s among just 23 AIDS patients with
known TB disease of whom two had a TST of 5–9 mm
induration while 13 had an induration ≥10 mm [4].
However, the incremental proportion of individuals defined as TST-positive when using this revised cut-off and
the variables such as CD4+ cell count that might be associated with this proportion are not known.
Cobelens and colleagues [5] investigated TST responses among a large number of PLWH who were diagnosed as having active smear-positive pulmonary
tuberculosis (TB) in Tanzania. Although just 71.2% of
patients tested TST-positive when using the recommended cut-off of ≥5 mm of induration, this did not
differ substantially from the proportion defined as positive using a cut-off of ≥10 mm of induration (64.3%)
with a difference of just 6.9%. Thus, the altered cut-off
only marginally reduced the number of false-negative
tests. The authors concluded from their data that loss of
sensitivity of the TST in PLWH is predominantly attributable to anergy (ie an all-or-nothing phenomenon) rather than due to a gradual diminution in TST diameter
during progressive immunodeficiency. However, this
study was conducted solely among PLWH who had
active TB and these findings cannot necessarily be extrapolated to those with latent MTB infection and any
association with CD4+ cell count was not defined.
We previously conducted a systematic review of the literature to ascertain the proportions of PLWH who tested
TST-positive using the conventional cut-off of ≥5 mm of
induration [6]. In the present systematic review, we determined the proportions of PLWH testing TST-positive
using cut-offs of ≥5 mm and ≥10 mm cut-off and the relationship with CD4+ cell count.
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Methods
Search strategy

The search strategy has been described in detail elsewhere [6]. In brief, we searched Embase, Global Health,
Medline and Web of Science for relevant citations using
a combination of MeSH and free text search terms
according to a predetermined search criteria. The search
was restricted to articles from January 1, 1990 to February 5, 2012 as an initial search demonstrated no relevant
citations prior to this period. The first search set was
created using comprehensive search terms for tuberculin
skin test, latent tuberculosis and isoniazid preventive
therapy and were combined using “or.” A second set was
created for HIV/AIDS using comprehensive search
terms. These two sets were then combined using “and.”
Next, this set was combined with a low and middleincome country (LMIC) set (using the World Bank list
of economies as of 01 July 2011) [7] using “and.” All citations were then limited to articles published in English
and among humans.
Studies eligible for inclusion were those that were
conducted in LMIC’s, included only PLWH who were at
least 15 years of age, presented data for patients without
evidence of active TB disease, and presented the proportion of those testing TST-positive current using a induration cut-off size of both ≥5 mm and ≥10 mm. Studies
were also required to have at least 30 participants meeting the above criteria to limit imprecision around the
point estimates. Studies utilizing two-step TST testing
were excluded. All studies meeting the aforementioned
criteria were included regardless of patient ART status at
enrolment.
Citations identified through the search process were
compiled into Endnote where duplicate citations were
removed. Titles and abstracts were screened for study
inclusion. Potentially relevant full-text citations were
entered into an Excel spreadsheet and the full-texts were
obtained. Two readers (ADK and SDL) carefully reviewed all full-text publications for study inclusion.
Additional studies met the inclusion criteria following
provision of additional data by the authors as previously
described [6].
Data extraction

Study characteristics from eligible studies were abstracted
directly into a structured Microsoft Excel spreadsheet.
Variables recorded included: title, authors, year of publication, study period, study location, clinical setting, mean or
median patient age, bacille Calmette et Guerin (BCG)
vaccine scar status, ART status, special or potentially nongeneralizable populations and the total number of eligible
PLWH who underwent TST testing (and returned to have
their results read) and the total number PLWH testing
TST-positive using both a ≥5 mm and a ≥10 mm
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induration size. When TST-results using both a ≥5 mm
and a ≥10 mm cut-off stratified by CD4+ cell counts
(<200, 200–499 and ≥500 cells/μL) were available, these
were also recorded.
The quality of studies was independently assessed by
two reviewers (ADK and SDL) using a graded checklist
[6]. A study receiving 70% of available points was considered to be of “good quality”, 50-70% was considered
“medium quality” and less than 50% was considered
“lower quality.” We also assessed the risk of bias in individual studies as well as across all included studies.
Statistical analysis

All statistical analysis was completed using STATA version
10.0. The difference in the proportion of those testing
TST-positive using a ≥5 mm versus a ≥10 mm cut-off was
calculated for all eligible studies and chi-squared tests
were used to compare these proportions. Differences in
the proportions of PLWH testing TST-positive by each
cut-off size were then plotted using a forest plot and were
stratified by geographic region and CD4+ cell count.
Pooled estimates of overall data or stratified data were not
derived due to substantial heterogeneity between studies
as indicated by large I2 values [8].

Results
Of the 3,095 potential citations identified in the literature
search, 254 were selected for full-text review (Figure 1).
After concluding a full-text review, 24 articles met the
pre-defined inclusion criteria and an additional 8 articles
met inclusion criteria due to unpublished data provided
by authors for a previous study. In all, 32 publications
provided data from 34 unique study populations and
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were published between 1992 and 2011 (Additional file 1).
Among included publications, 14 study populations were
from Africa, 8 from the Americas and 12 from Asia. The
TB prevalence in counties in which the studies were
conducted ranged from 0.19-785 cases per 100,000 population and the majority (62%; 21/34) of study populations
were from high-prevalence TB countries (estimated TB
prevalence >100 cases per 100,000 population).
The mean/median age among patients in eligible studies ranged from 22–42 years. The proportions of PLWH
on ART at the time of TST assessment was reported for
18 study populations and an additional six study populations were assumed to be ART naïve as the studies were
conducted prior to national ART implementation. Among
these 24 populations, ART was received by a proportion
of the participants in only 9 studies and this proportion
varied from 1% to 100% (median 58%). Nine publications
were of high quality, 12 studies of medium quality and 11
studies of low quality, as determined by a quality assessment checklist.
Difference in patients testing TST-positive using a ≥5 mm
versus ≥10 mm cut-off size

Overall, there were 10,971 PLWH with TST results from
34 study populations; 4,880 were from sub-Saharan
Africa, 2,247 from the Americas and 3,844 from Asia.
All studies reported the proportion of individuals testing
TST-positive using both a 5 mm and 10 mm cut-off
(Table 1).
The median proportion of PLWH testing TST-positive
using a cut-off of ≥5 mm was 26.8% (IQR, 19.8-46.1%;
range 2.5-81.0%). There was considerable heterogeneity
with regard to regional differences in the proportion of

Figure 1 Overview of eligible studies containing data on the proportion of people living with HIV testing TST-positive using a ≥5 mm
and ≥10 mm cut-off size.
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Table 1 The proportion of people living with HIV who tested TST-positive using a ≥5 mm and ≥10 mm cutoff size and
the difference between these two proportions
Study

Number of
patients (n)

Number of patients
TST-positive using
≥5 mm cut-off (%)

Number of patients
TST-positive using
≥10 mm cut-off (%)

Difference in proportion
of patients testing
TST-positive (%)

P-value

Africa
Allen et al. [9]

284

73 (25.7)

60 (21.1)

4.6

0.1977

Aisu et al. [10]

1094

579 (52.9)

376 (34.4)

18.6

<0.0001

Duncan et al. [11]

106

35 (33.0)

32 (30.2)

2.8

0.6576

Fordham von Reyn et al. [12]

104

21 (20.2)

20 (19.2)

1.0

0.8616

Diagbouga et al. [13]

37

9 (24.3)

6 (16.2)

1.7

0.3857

Waddell et al. [14]

58

16 (27.6)

15 (25.9)

8.1

0.8338

Mtei et al. [15]

460

192 (41.7)

175 (38.0)

3.7

0.2524

Tegbaru et al. [16]

116

47 (40.5)

38 (32.8)

7.8

0.2201

Rangaka et al. [17]

67

35 (52.2)

33 (49.3)

3.0

0.7297

Karam et al. [18]

273

59 (21.6)

46 (16.8)

4.8

0.1581

Hanifa et al. [19]

33

18 (54.5)

14 (42.4)

12.1

0.3245

Leidl et al. [20]

89

42 (47.2)

35 (39.3)

7.9

0.2896

Oni et al. [21]

240

138 (57.5)

125 (52.1)

5.4

0.2332

Samandari et al. [22]

1919

468 (24.4)

383 (20.0)

4.4

0.0010

Espinal et al. [23]

86

50 (58.1)

40 (46.5)

11.6

0.1269

Fordham von Reyn et al. [12]

121

3 (2.5)

2 (1.7)

0.8

0.6513

Garcia-Garcia et al. [24]

801

261 (32.6)

174 (21.7)

10.9

<0.0001

Miranda et al. [25]

98

16 (16.3)

12 (12.2)

4.6

0.4142

Balcells et al. [26]

109

12 (11.0)

7 (6.4)

4.1

0.2299

The Americas

Gutierrez et al. [27]

104

20 (19.2)

13 (12.5)

6.7

0.184

Baboolal et al. [28]

64

6 (9.4)

0

9.4

0.0121

Moura et al. [29]

864

170 (19.7)

152 (17.6)

2.1

0.2661

Suwanagool et al. [30]

399

323 (81.0)

173 (43.4)

37.6

<0.0001

Yanai et al. [31]

217

46 (21.2)

32 (14.7)

6.5

0.0801

Yanai et al. [31]

129

21 (16.3)

15 (11.6)

4.7

0.281

Sawhney et al. [32]

396

103 (26.0)

62 (15.7)

10.4

0.0003

Asia

Gupta et al. [33]

752

157 (20.9)

137 (18.2)

2.7

0.1935

Swaminathan et al. [34]

631

269 (42.6)

227 (36.0)

6.7

0.0155

Davarpanah et al. [35]

173

64 (37.0)

23 (13.3)

23.7

<0.0001

Davarpanah et al. [36]

459

131 (28.5)

60 (13.1)

15.5

<0.0001

Jiang et al. [37]

46

27 (58.7)

17 (37.0)

21.7

0.0369

Zhang et al. [38]

93

3 (3.2)

3 (3.2)

0

1

Kabeer et al. [39]

180

33 (18.3)

27 (15.0)

3.3

0.3961

Nguyen et al. [40]

369

204 (55.3)

175 (47.4)

8.1

0.0274

patients testing TST-positive. The median proportions
of patients testing TST-positive in sub-Saharan Africa,
the Americas and Asia were 36.8% (IQR, 24.7-51.0%;
range, 20.2-57.5%), 17.8% (IQR, 10.6-22.9%; range, 2.5-

58.1%), and 27.3% (IQR, 20.3-45.8%; range, 3.2-81.0%),
respectively.
When a cut-off of ≥10 mm was used, the median proportion of patients testing TST-positive was 19.6% (IQR,
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a

b

Figure 2 Forest plot showing the difference in proportions (%, 95% CI) of people living with HIV testing TST-positive using a ≥5 mm
versus a ≥10 mm cut-off size in (a) all study populations (n = 34) and (b) with data grouped according to region.

Study
Gupta et al. [33]
Rangaka et al. [17]
Karam et al. [18]
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Table 2 The proportion of people living with HIV who tested TST-positive using a ≥5 mm and ≥10 mm cutoff size stratified by CD4+ cell count categories
<200, ≥200, 200–499 and ≥500 cells/μL
Number of
Number of
Number of
Number of
Number of
Number of
Number of
Number of
Number of
patients with
patients TST
patients TST
patients with
patients TST
patients TST
patients with
patients TST
patients TST
CD4+ cell
positive using
positive using
CD4+ cell
positive using
positive using
CD4+ cell
positive using
positive using
count <200 ≥5 mm cutoff (%) ≥10 mm cutoff (%) count 200-499 ≥5 mm cutoff (%) ≥10 mm cutoff (%) count ≥500 ≥5 mm cutoff (%) ≥10 mm cutoff (%)
50

8 (16.0)

7 (14.0)

326

71 (21.8)

66 (20.2)

307

65 (21.2)

56 (18.2)

8

2 (25.0)

2 (25.0)

31

17 (54.8)

16 (51.6)

18

11 (61.1)

10 (55.6)

145

11 (7.6)

10 (6.9)

85

25 (29.4)

22 (25.9)

43

23 (53.5)

14 (32.6)

Balcells et al. [26]

13

1 (7.7)

1 (7.7)

73

4 (5.5)

2 (2.7)

23

7 (30.4)

4 (17.4)

Swaminathan et al. [34]

150

64 (42.7)

48 (32.0)

313

138 (44.1)

117 (37.4)

160

67 (41.9)

62 (38.8)

Moura et al. [29]

137

13 (9.5)

13 (9.5)

386

70 (18.1)

61 (15.8)

341

87 (25.5)

78 (22.9)

Nguyen et al. [40]

75

31 (41.3)

24 (32.0)

206

116 (56.3)

100 (48.5)

88

57 (64.8)

51 (58.0)

Oni et al. [21]

51

25 (49.0)

21 (41.2)

137

79 (57.7)

73 (53.3)

50

33 (66.0)

30 (60.0)

Samandari et al. [22]

575

88 (15.3)

74 (12.9)

952

250 (26.3)

212 (22.3)

364

124 (34.1)

93 (25.6)
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13.7-36.8%; range, 0–52.1%). Strong regional differences
in the proportion of patients TST-positive were again
noted. Patients in sub-Saharan Africa had a median
TST-positive proportion of 31.5% (IQR, 20.3-39.0%;
range, 16.2-52.1%) compared to 12.4% (IQR, 5.2-18.6%;
range, 0–46.5%) in the Americas and 15.4% (IQR, 13.336.3%; range, 3.2-47.4%) in Asia.
The median difference observed in the proportion of
those testing TST-positive using a cut-off size of ≥5 mm
versus ≥10 mm was 6.0% (IQR, 3.4-10.1%; range 0–
37.6%). When stratified by geographic region, the median difference in the proportion of patients testing
TST-positive using a 5 mm versus a 10 mm cut-off was
4.7% (IQR, 3.1-7.9%, range, 1.0-18.6%), 5.7% (IQR, 3.69.8%, range, 0.8-11.6%) and 7.3% (IQR, 4.4-17.0%, range,
0–37.6%) for Africa, the Americas and Asia respectively.
The overall difference in the proportions of patients
testing TST positive (Figure 2a) and stratified according
to geographic region (Figure 2b) was demonstrated in
forest plots.
Association with CD4+ cell counts

Nine studies with a total of 5,107 PLWH reported the proportion of those testing TST-positive using both a ≥5 mm

Page 7 of 9

and a ≥10 mm cut-off size stratified by CD4+ cell counts
at <200, 200–499, ≥500 (Table 2). These CD4+ cell count
stratified data are shown in a forest plot (Figure 3). The
median difference in the proportion of PLWH testing
TST-positive using the two induration cut-off sizes was
2.0% (range, 0–10.7%; IQR, 0–7.8%), 3.5% (range, 1.57.8%; IQR, 2.7-4.4%) and 6.0% (range, 2.6-20.9%; IQR, 4.99.6%) among those with CD4+ cell counts <200, 200–499,
≥500 cells/μL, respectively. The corresponding proportions of positive tests defined by the ≥5 mm cut-off that
were between 5.0 and 9.9 mm in diameter were 12.5%
(IQR, 0–16.0), 12.9% (IQR, 7.6-15.2), 10.5% (IQR, 9.128.5), respectively [9-40].

Discussion
This study found that among 10,971 patients without active TB in 34 different study populations, the incremental yield of patients defined as TST-positive when using
a ≥5 mm cut-off rather than a ≥10 mm cut-off was just
6.0%. This suggests that using the modified cut-off had
only a modest effect on increasing the proportion of
PLWH who tested TST-positive. Importantly, this proportion was similar across the range of CD4+ cell count
strata and also across different geographic regions.

Figure 3 Forest plot showing the difference in proportions (%, 95% CI) of people living with HIV testing TST-positive using a ≥5 mm
versus a ≥10 mm cut-off size with data grouped according to CD4+ cell count strata (<200, 200–499 and ≥500 cells/μL).
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Our findings of a 6% incremental proportion associated
with the use of the revised TST cut-off among patients
without active TB are very similar to those of Cobelens
and colleagues [5] who reported a 7% increment among
patients with active TB in Tanzania. This suggests that the
small differences observed in the proportion of PLWH
testing TST-positive using the two cut-off sizes are
generalizable regardless of TB infection or disease status.
A recent systematic review and meta-analysis [41] investigated the utility of ≥5 mm and ≥10 mm TST cut-off
sizes to predict the progression from latent infection to
active TB disease. Among five studies in which the HIV
status of patients was largely unknown, the unadjusted
incidence rate ratio of tuberculosis in TST-positive
patients was 1.43 (95% CI, 0.75-2.72) when a cut-off of
≥5 mm was used and 1.60 (95% CI, 0.94-2.72) when a
cut-off ≥10 mm was applied. Thus, neither cut-off size
better predicted the risk for progression to active TB
disease. However, because the HIV status of the patients
included in these studies was negative or largely unknown, it remains unclear whether these findings are
generalizable to PLWH.
TSTs rather than IGRAs are the WHO-recommended
assay for use in LMICs for detecting latent tuberculosis
infection among PLWH prior to isoniazid preventive
therapy [42]. Although use of TST is recommended, it
remains unknown whether a ≥5 mm or ≥10 mm cut-off
size better defines those who will benefit from IPT. A
meta-analysis [43] among PLWH demonstrated that
among those with a TST induration of ≥5 mm in diameter, IPT was associated with a TB risk reduction of 64%
(95% CI, 39-78 %). However, all studies in this metaanalysis defined TST-positivity using a ≥5 mm cut-off
size and thus it is not known whether those with a 5.09.9 mm induration gain benefit from IPT. An individual
patient meta-analysis of data from randomized trials of
isoniazid preventive therapy may be able to define this.
Strengths of this study include a comprehensive search
strategy that utilized four different study databases. There
were more than 10,000 patients from 34 unique study
populations from many countries and geographic regions.
Also, a number of variables potentially influencing differences in the proportion of TST-positive patients were
recorded and summarized where possible. There were also
several limitations. The reliability of TST assessment could
not be assessed. Additionally, methods for excluding TB
disease were not standardized among included studies.
Heterogeneity in the data precluded the calculation of
pooled summary estimates.

Conclusion
In conclusion, using a ≥5 mm cut-off among PLWH
resulted in only a modest increase in the proportion testing TST-positive when compared to a cut-off size of
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≥10 mm and this finding concurs with a similar study that
was conducted among patients with active TB. The difference in the proportion of PLWH testing TST-positive
when using the two different cut-off sizes was similar
across the range of CD4+ cell count strata suggesting use
of this cut-off across the spectrum of immunodeficiency.

Additional file
Additional file 1: Characteristics of studies presenting data on the
proportion of HIV-infected patients who tested TST-positive using a
≥5 mm and ≥10 mm cut-off size.
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